Adaptimmune Therapeutics logo

ADAP - Adaptimmune Therapeutics News Story

$4.13 0.3  7.0%

Last Trade - 6:45pm

Mid Cap
Market Cap £435.4m
Enterprise Value £207.1m
Revenue £2.61m
Position in Universe 3434th / 6938

Adaptimmune Therapeutics PLC reports results for the quarter ended in March - Earnings Summary

Thu 6th May, 2021 7:11pm
* Adaptimmune Therapeutics PLC  ADAP.OQ  reported a quarterly
adjusted loss of 24 cents​​ per share for the quarter ended
in March. The mean expectation of six analysts for the quarter
was for a loss of 25 cents per share.
* Revenue fell 43% to $434.00 thousand from a year ago​; 
analysts expected $1.83 million.
* Adaptimmune Therapeutics PLC's reported EPS for the quarter
was a loss of 24 cents​.
* The mean earnings estimate of analysts had fallen by
about 0.3% in the last three months.​ 
* In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
* Adaptimmune Therapeutics PLC shares had fallen by 3.6% this
quarter and lost 5.0% so far this year.
* The company reported a quarterly loss of $37.76 million.
* Wall Street's median 12-month price target for Adaptimmune
Therapeutics PLC is $12.00 
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 4 "strong buy" or "buy," 4
"hold" and no "sell" or "strong sell." 
This summary was machine generated May 6 at 06:11 p.m. GMT. ​All
figures in US Dollars.​
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.